Navigation Links
Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Date:12/2/2008

PITTSBURGH, Dec. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Novartis Pharmaceuticals Corp., Novartis Corp. and Novartis International AG related to Letrozole Tablets, the generic version of Novartis' Femara(R).

Mylan's Vice Chairman and CEO Robert J. Coury commented: "We are very pleased to have reached this agreement, which demonstrates our ability to once again bring to market high quality, affordable medications for the patients who need them the most."

Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole Tablets, 2.5 mg, prior to the expiration of U.S. Patent No. 4,978,672. Additional terms related to the settlement remain confidential, and the agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Letrozole Tablets, which are used in the treatment of breast cancer, had U.S. sales of approximately $470 million for the 12 months ending Sept. 30.

Mylan was the first company to file a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for the product. Currently, Mylan has 113 ANDAs pending U.S. Food and Drug Administration approval, 24 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement, regulatory approvals and Mylan's future business opportunities. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
2. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
5. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
6. Mylan to Offer $400 Million in Cash Convertible Notes
7. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
8. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
11. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway ... now offering HIAC particle counting and sizing services for USP 788 and 789 ... the new service as a response to the needs of pharmaceutical and medical ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... focused on providing occupational safety and health training to public sector employees. , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... ... 05, 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to ... Over the course of three years, researchers will study concussions and changes in brain ... equipped with special sensors, will track the location and force of the hit. The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5 2016 United Kingdom Ophthalmic ... GlobalData,s new report, "United Kingdom Ophthalmic Diagnostic ... data on the United Kingdom Ophthalmic Diagnostic Equipment ... US dollars, volume (in units) and average prices ... (OCT), Retinal Ultrasound Imaging Systems, Corneal Topography Systems, ...
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: